about
The 5-HT3 receptor as a therapeutic targetEscherichia coli Nissle 1917 enhances bioavailability of serotonin in gut tissues through modulation of synthesis and clearance.Functional GI disorders: from animal models to drug development.5-HT₃ antagonists under development.Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets.Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicineGuidelines on the irritable bowel syndrome: mechanisms and practical management.Enteric P2X receptors as potential targets for drug treatment of the irritable bowel syndromeThe safety of drugs used in acid-related disorders and functional gastrointestinal disorders.Making decisions about benefits and harms of medicines.Aminophylline suppresses stress-induced visceral hypersensitivity and defecation in irritable bowel syndrome.Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist.Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective.Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease.Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot studyThe HTR3A polymorphism c. -42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome.The brain-gut axis in abdominal pain syndromes.Acute tryptophan depletion alters the effective connectivity of emotional arousal circuitry during visceral stimuli in healthy women.Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome.Serotonin and superior mesenteric artery resistance index.Pathological Conditions Associated with the Disturbance of the 5-HT System
P2860
Q24681066-A31F6924-6123-47EC-A7A2-0BB38D099922Q27304899-6A21458C-3406-4F37-8002-F08856AE11B3Q30433078-F2FD1F4B-251F-4974-9504-20C077BD995AQ33719742-A2D9AD03-4EF7-4F34-825B-518E66E30F6DQ33724343-F35AC858-CB0E-4A32-AA53-D4DC932A2E79Q33735229-4B54E5BC-D0DA-464F-AF86-55F8F4472A17Q34626602-282DDF2C-F67F-4D59-B4EF-413F1C22C547Q35047062-9B736F3D-90A2-4BF7-95A0-48CA072931DEQ35052602-9B9F197A-9FC1-4CB7-828D-E6E6EBF9478CQ35615569-CDE10ECE-DECB-449C-92AB-5FB1005E4275Q36240095-198E9CED-6E71-4BFA-8CDE-0D353C8E3FD9Q36382976-76A4ED19-2D5A-43EE-B384-CB79C862A610Q36536707-2413191A-9ACA-45A0-BACE-2E346AA12F59Q36583822-802F0A67-87B5-4074-A69B-C8FA16D963B2Q37130193-2F698EE5-164D-46D1-934D-43C2EB316F0EQ37134075-16B379E9-0BA9-4E22-8E02-58E20F323F81Q37280260-A4ADE559-34F3-452D-8B44-29B648220705Q37412200-96112583-FD09-4D14-94C2-2AE8AE944A9FQ37426287-3630D5BC-E108-4E53-B761-6FA2EDE9035BQ51492553-D9894F07-CCB5-4C5D-86E1-43572ACD40DDQ59201274-F3996CC7-F113-4136-9845-275CD4587E34
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Alosetron and irritable bowel syndrome.
@ast
Alosetron and irritable bowel syndrome.
@en
Alosetron and irritable bowel syndrome.
@nl
type
label
Alosetron and irritable bowel syndrome.
@ast
Alosetron and irritable bowel syndrome.
@en
Alosetron and irritable bowel syndrome.
@nl
prefLabel
Alosetron and irritable bowel syndrome.
@ast
Alosetron and irritable bowel syndrome.
@en
Alosetron and irritable bowel syndrome.
@nl
P2860
P1476
Alosetron and irritable bowel syndrome.
@en
P2093
Emeran A Mayer
Sylvie Bradesi
P2860
P304
P356
10.1517/14656566.4.11.2089
P407
P577
2003-11-01T00:00:00Z